Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Guanosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | TGM2 | P21980 | 1/20 | 0.66 |
| ▸ | HINT1 | P49773 | 4/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.61 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 4/20 | 0.60 |
| ▸ | GSK3A | P49840 | 2/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.60 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL31361372 | 1.00 | NT5E (0.72) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL94793 | 1.00 | NT5E (0.72) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL1304255 | 1.00 | NT5E (0.72) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL376138 | 1.00 | NT5E (0.72) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL44407 | 1.00 | NT5E (0.72) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL8719176 | 0.99 | NT5E (0.70) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL29220760 | 0.97 | NT5E (0.68) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL5356557 | 0.97 | NT5E (0.70) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL9238739 | 0.96 | NT5E (0.69) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL1444901 | 0.96 | NT5E (0.69) | NT5EHPGDTGM2HINT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709736-A2 | COMBINATIONS OF NANOPARTICLE-LOADED IMMUNE AGONISTS AND RAS TARGETED THERAPIES FOR TREATMENT OF CANCER | University Of Massachusetts (US) | 2026-03-18 | — | — | EP | claimed |
| WO-2024238486-A2 | COMBINATIONS OF NANOPARTICLE-LOADED IMMUNE AGONISTS AND RAS TARGETED THERAPIES FOR TREATMENT OF CANCER | UNIVERSITY OF MASSACHUSETTS (US) | 2024-11-21 | — | — | WO | claimed |
| EP-3770265-B1 | METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID PARTICLES FOR TREATING CANCER | INST CURIE (FR) | 2023-10-11 | — | — | EP | claimed |
| EP-2547361-B1 | BACTERIAL VACCINE COMPONENTS FROM STAPHYLOCOCCUS AUREUS AND USES THEREOF | SOCPRA SCIENCES ET GENIE SEC (CA) | 2020-10-28 | — | — | EP | claimed |
| EP-4719340-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION | Inhatarget Therapeutics (BE) | 2026-04-08 | — | — | EP | disclosed |
| US-12274744-B2 | Biomaterials for modulating immune responses | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-04-15 | — | — | US | disclosed |
| WO-2024246303-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION | INHATARGET THERAPEUTICS (BE) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024246304-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION | INHATARGET THERAPEUTICS (BE) | 2024-12-05 | — | — | WO | disclosed |
| US-11786457-B2 | Peritumoral and intratumoral materials for cancer therapy | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-10-17 | — | — | US | disclosed |
| CN-115515968-A | Allele-specific silencing of transforming growth factor beta-inducible genes with R124H mutation using short interfering RNA | 阿维利诺美国实验室股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-3737752-A1 | REGULATION OF CSR SYSTEM FOR PRODUCTION OF LYSINE AND LYSINE-DERIVED PRODUCTS | Cathay Biotech Inc. (CN) | 2020-11-18 | — | — | EP | disclosed |
| WO-2019136585-A1 | REGULATION OF CSR SYSTEM FOR PRODUCTION OF LYSINE AND LYSINE-DERIVED PRODUCTS | CATHAY R & D CENTER CO., LTD. (CN) | 2019-07-18 | — | — | WO | disclosed |
| EP-3497226-A1 | CONTROL OF BIOFILM DISPERSAL FOR THE PRODUCTION OF AMINO ACIDS OR AMINO ACID-DERIVED PRODUCTS | Shanghai Cathay Biotech R&D Center Ltd. (CN) | 2019-06-19 | — | — | EP | disclosed |
| WO-2018032240-A1 | CONTROL OF BIOFILM DISPERSAL FOR THE PRODUCTION OF AMINO ACIDS OR AMINO ACID-DERIVED PRODUCTS | CATHAY R&D CENTER CO., LTD. (CN) | 2018-02-22 | — | — | WO | disclosed |
| EP-2566963-B1 | SENSORS FOR THE DETECTION OF INTRACELLULAR METABOLITES | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2015-10-21 | — | — | EP | disclosed |
| EP-2566963-A1 | SENSORS FOR THE DETECTION OF INTRACELLULAR METABOLITES | Forschungszentrum Jülich Gmbh (DE) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138006-A1 | SENSORS FOR THE DETECTION OF INTRACELLULAR METABOLITES | Forschungszentrum Jülich GmbH (DE) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786457-B2 | Peritumoral and intratumoral materials for cancer therapy | CD47, CD68, GZMB | NT5E 873/4885HPGD 830/4885TGM2 1099/4885 |
| US-12274744-B2 | Biomaterials for modulating immune responses | CD47, CD14, TLR3 | NT5E 2669/4885HPGD 1241/4885TGM2 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.